Routine vaccines

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines, GlaxoSmithKline

Conditions

Infections, MeningococcalMeningococcal DiseaseMeningococcal Meningitis

Phase 3

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

CompletedNCT01214837

Novartis VaccinesMeningococcal Disease, Meningococcal Meningitis

Start: 2010-10-31End: 2012-05-31Updated: 2018-10-09

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

CompletedNCT02173704

GlaxoSmithKlineInfections, Meningococcal, Meningococcal Disease

Start: 2014-09-11End: 2016-06-17Updated: 2020-08-25

Related Papers

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study

Human Vaccines & Immunotherapeutics2018-01-1614 citations

Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants

The Pediatric Infectious Disease Journal2015-10-1713 citations